Lisinopril

CHEMBL419213 Phase 4 已批准 Small molecule
Half-Life
12 hours
Bioavailability
Protein Binding
Molecular Weight
405.5 g/mol
LogP
-2.9
Phase
4

An ACE inhibitor used to treat high blood pressure, heart failure, and kidney disease, and studied in bladder cancer and atrial fibrillation. It reduces blood pressure by preventing the production of angiotensin II, a hormone that narrows blood vessels.

分子量

405.4900 g/mol

LogP

-2.90

TPSA

133.00 Ų

Lipinski 五规则

符合

治疗领域

药物分类

作用机制

ACE inhibitor preventing conversion of angiotensin I to angiotensin II.

Pharmacokinetics (PK)

Half-Life 12 hours

Pharmacodynamics (PD)

机制

ACE inhibitor preventing conversion of angiotensin I to angiotensin II.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O

InChI

InChI=1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

Molecular Formula

C21H31N3O5

HBD / HBA

4 / 7

可旋转键数

12

重原子数

29

Primary Target
Major Lisinopril + Losartan

Dual RAAS blockade with ACE inhibitors and ARBs provides no additional cardiovascular benefit over either agent alone and significantly increases the risk of hypotension, hyperkalemia, and acute kidney injury.

Major Lisinopril + Lithium Carbonate

ACE inhibitors like lisinopril reduce renal lithium excretion, causing potentially dangerous lithium toxicity.

Minor Lisinopril + Metformin

ACE inhibitors may increase insulin sensitivity and reduce blood glucose, occasionally causing hypoglycemia in diabetic patients also using antidiabetic agents including metformin.

Moderate Lisinopril + Spironolactone

Adding spironolactone to an ACE inhibitor substantially increases the risk of hyperkalemia, which can cause life-threatening cardiac arrhythmias.

Minor Lisinopril + Amlodipine

The combination of amlodipine and lisinopril provides complementary antihypertensive mechanisms and may cause additive hypotension, particularly with initial dosing.

Minor Lisinopril + Carvedilol

Combined use of carvedilol and lisinopril in heart failure is guideline-recommended but carries additive hypotensive risk, particularly with initiation or dose uptitration.

Minor Lisinopril + Hydrochlorothiazide

The ACE inhibitor and thiazide combination is guideline-recommended for hypertension but can cause first-dose hypotension and metabolic disturbances including hypokalemia or hyperkalemia.

Moderate Lisinopril + Ibuprofen

NSAIDs reduce the antihypertensive and renoprotective efficacy of ACE inhibitors and can precipitate acute kidney injury, particularly in volume-depleted or elderly patients.

Moderate Lisinopril + Celecoxib

Celecoxib, a selective COX-2 inhibitor, attenuates the antihypertensive effect of lisinopril and increases the risk of renal impairment.

Moderate Lisinopril + Furosemide

ACE inhibitors combined with loop diuretics can cause first-dose hypotension and acute kidney injury, particularly in volume-depleted patients.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

An ACE inhibitor used to treat high blood pressure, heart failure, and kidney disease, and studied in bladder cancer and atrial fibrillation. It reduces blood pressure by preventing the production of angiotensin II, a hormone that narrows blood vessels.

ACE inhibitor preventing conversion of angiotensin I to angiotensin II.

Key pharmacokinetic parameters for Lisinopril: Half-life: 12 hours.

Yes, Lisinopril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL419213. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5362119. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.